BRIGHT-DATA
12.9.2022 15:23:36 CEST | Business Wire | Press release
Bright Data, the industry-leading web data platform, has today announced the acquisition of eCommerce insights provider Market Beyond. With this acquisition, Bright Data adds digital shelf analytics to its already comprehensive data offerings, introducing its new division – Bright Insights.
Market Beyond’s team will join Bright Data’s 400+-strong team, where they will lead the newly established Bright Insights division. This dedicated team will roll out Bright Insights to the company’s enterprise retail customer base with plans to expand in the future to further domains.
Through Bright Insights, leading retail brands, marketplaces and manufacturers will now be able to gain quality, reliable web data as well as critical business insights from one place. This will allow prominent brands to create strategies based on quality-driven data insights and, in turn, optimize and advance their business performance.
Since launching in Tel Aviv, Israel, in 2016, Market Beyond has worked with large manufacturers and brands within the eCommerce sphere to provide an accurate picture of both their and their competitors’ market share in the eCommerce landscape. Market Beyond has grown significantly and now has a global footprint with a dedicated US focus, where its customer base includes multiple Fortune 500 brands, such as Home Depot, eBay, Overstock and many more.
“The acquisition of Market Beyond, and the subsequent launch of Bright Insights, will allow retail sphere leaders to seamlessly get the real-time web data they need as well as the actionable insights crucial for split-second decision-making,” said Bright Data CEO Or Lenchner. “Bright Data’s focus on innovating web data products supports thousands of customers around the world. The introduction of Bright Insights will take data analysis to the next level. We look forward to welcoming the Market Beyond team into Bright Data's expanding family, and we are excited about the positive impact this will have on the data industry,” concluded Lenchner.
“This partnership not only signals a new chapter for Market Beyond but affirms our commitment to providing market-leading data-driven insights to leading businesses around the world,” said Market Beyond CEO Yuval Yifrach. “Market Beyond’s capabilities complement Bright Data’s industry-first technology perfectly. This deal, as well as the launch of Bright Insights, will allow us to continue providing market intelligence to brands and retailers and extend our reach to new markets. We have been working closely with Bright Data’s technology for over two years and we look forward to continuing to work alongside the entire Bright Data team as we create Bright Insights and push the boundaries of what is possible within the data-driven analysis space.”
-ENDS-
About Market Beyond
Since its establishment in 2016, Market Beyond’s unique AI & Machine Learning technology has served the largest brands across the world, specifically the market-leading brands, Fortune 500 included, in the US. Today, Market Beyond provides its dozens of customers in the retail space with reliable and precise real-time market insights that directly impact their present landscape as well as future strategic steps.
About Bright Data
Bright Data is the industry-leading web data platform. Fortune 500 companies, academic institutions, and small businesses rely on Bright Data’s solutions to retrieve public web data in the most efficient, reliable, and flexible way so they can research, monitor, and train their systems and analyze data to run better strategies and inform decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom